Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate

Biochemical Pharmacology

Volumn 56, Issue 12, 1998, Pages 1583-1589

  Tramontano, Enzo ^a   Piras, Giovanna ^a   Mellors, John W ^b   Putzolu, Monica ^a   Bazmi, Hengameh Z ^b   La Colla, Paolo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; foscarnet; HIV 1; PFA; Resistance; Reverse transcriptase

Indexed keywords

4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; AMINO ACID; FOSCARNET; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MICHAELIS CONSTANT; NONHUMAN; PLOTS AND CURVES; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACIDS; DIPHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENZYME STABILITY; FOSCARNET; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MUTAGENESIS, SITE-DIRECTED; NEVIRAPINE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0031743582     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00206-8     Document Type: Article

References (27)

1. Oberg B, Antiviral Effects of phosphonoformate (PFA, Foscarnet sodium). Pharmacol Ther 40: 213-285, 1989.
2. Field AK and Biron KK, "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev 7: 1-13, 1994.
3. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB and Jacobson MA, Effect of Foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J Infect Dis 166: 607-610, 1992.
4. Fletcher CV, Collier AC, Rhame FS, Bennett D, Para MF, Beatty CC, Jones CE and Balfour HH Jr., Foscarnet suppression of human immunodeficiency virus replication. Antimicrob Agents Chemother 38: 604-607, 1994.
5. Kaiser L, Perrin L, Hirschel B, Furrer H, Von Overbeck J, Olmari M and Yerly S, Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis 172: 225-227, 1995.
6. Balfour HH, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA and Martin Munley SS, Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother 40: 2721-2726, 1996.
7. Crumpacker CS, Mechanism of action of Foscarnet against viral polymerases. Am J Med 92: 3S-7S, 1992.
8. Sullivan V and Coen DM, Isolation of Foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 164: 781-784, 1991.
9. D'Aquila RT and Summers WC, Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus. J Virol 61: 1291-1295, 1987.
10. Baldanti F, Underwood MR, Stanat SC, Biron KK, Chou S, Sarasini A, Silini E and Gerna G, Single amino acid changes in the DNA polymerase confer Foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer Ganciclovir resistance in the three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 70: 1390-1395, 1996.
11. Mellors W, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J and Mayers DL, Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to Foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 39: 1087-1092, 1995.
12. Tachedjian G, Hooker DJ, Gurusinghe AD, Bazmi H, Deacon NJ, Mellors J, Birch C and Mills J, Characterization of Foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212: 58-68, 1995.
13. Jacobo-Molina A, Ding J, Nanni RG, Clark ADJr., Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH and Arnold E, Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 90: 6320-6324, 1993.
14. Mellors JW, Im G-J, Tramontano E, Winkler SR, Medina DJ, Dutschman GE, Bazmi HZ, Piras G, Gonzales CJ and Cheng Y-C, A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to ( + )-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4] benzodiazepin-2 (1H)thione. Mol Pharmacol 43: 11-16, 1993.
15. Tramontano E and Cheng Y-C, HIV-1 reverse transcriptase inhibition by a dypiridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 43: 1371-1376, 1992.
16. Prasad VR, Lowy I, de los Santos T, Chiang L and Goff SP, Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 88: 11363-11367, 1991.
17. Im GJ, Tramontano E, Gonzales CJ and Cheng Y-C, Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implication for multidrug resistance. Biochem Pharmacol 46: 2307-2313, 1993.
18. Derse D, Bastow KF and Cheng Y-C, Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J Biol Chem 257: 10251-10260, 1982.
19. Estaban JA, Bernad A, Salas M and Blanco L, Metal activation of synthetic and degradative activities of φ 29 DNA polymerase, a model enzyme for protein-primed DNA replication. Biochemistry 31: 350-359, 1992.
20. Wakefield JK, Jablonski SA and Morrow CD, In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral gene. J Virol 66: 6806-6812, 1992.
21. Wilson JE, Aulabaugh A, Caligan B, McPherson S, Wakefield JK, Jablonski S, Morrow CD, Reardon JE and Furman PA, Human immunodeficiency virus type-1 reverse transcriptase. Contribution of the Met-184 to binding of nucleoside 5′-triphosphate. J Biol Chem 271: 13656-13662, 1996.
22. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108, 1973.
23. Kellam P, Boucher CAB and Larder BA, Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934-1938, 1992.
24. Lacey SF, Reardon JE, Furfine ES, Kunkel, TA, Bebenek K, Eckert KA, Kemp D and Larder BA, Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 267: 15789-15794, 1992.
25. Spence RA, Kati WM, Anderson KS and Johnson KA, Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993, 1995.
26. De Clercq E, HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 52: 155-169, 1994.
27. Sardana VV, Emini EE, Gotlib L, Graham DJ, Lineberger DW, Long WJ, Schlabach AJ, Wolfang JA and Condra JH, Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem 267: 17526-17530, 1992.